Total Payments
$156,440
2024 Payments
$19,123
Companies
31
Transactions
534
Medicare Patients
8,272
Medicare Billing
$743,926
Payment Breakdown by Category
Other$83,064 (53.1%)
Consulting$41,779 (26.7%)
Travel$13,859 (8.9%)
Food & Beverage$11,686 (7.5%)
Research$5,885 (3.8%)
Education$166.80 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $83,064 | 56 | 53.1% |
| Consulting Fee | $41,779 | 17 | 26.7% |
| Travel and Lodging | $13,859 | 55 | 8.9% |
| Food and Beverage | $11,686 | 384 | 7.5% |
| Unspecified | $5,885 | 18 | 3.8% |
| Education | $166.80 | 4 | 0.1% |
Payments by Type
General
$150,555
516 transactions
Research
$5,885
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $114,664 | 186 | $0 (2024) |
| Mylan Specialty L.P. | $13,422 | 31 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $10,172 | 172 | $0 (2024) |
| EnsoData, Inc. | $7,500 | 2 | $0 (2024) |
| GlaxoSmithKline, LLC. | $2,148 | 70 | $0 (2024) |
| Eli Lilly and Company | $1,930 | 2 | $0 (2023) |
| Novo Nordisk AS | $1,628 | 4 | $0 (2017) |
| Chiesi USA, Inc. | $1,600 | 2 | $0 (2023) |
| AstraZeneca UK Limited | $1,337 | 7 | $0 (2018) |
| JAZZ PHARMACEUTICALS INC. | $635.50 | 6 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $19,123 | 61 | Mylan Specialty L.P. ($13,192) |
| 2023 | $5,604 | 48 | EnsoData, Inc. ($2,500) |
| 2022 | $5,879 | 57 | AstraZeneca Pharmaceuticals LP ($3,879) |
| 2021 | $7,447 | 50 | Boehringer Ingelheim Pharmaceuticals, Inc. ($6,299) |
| 2020 | $19,219 | 46 | Boehringer Ingelheim Pharmaceuticals, Inc. ($16,283) |
| 2019 | $40,320 | 97 | Boehringer Ingelheim Pharmaceuticals, Inc. ($37,600) |
| 2018 | $40,468 | 112 | Boehringer Ingelheim Pharmaceuticals, Inc. ($36,698) |
| 2017 | $18,380 | 63 | Boehringer Ingelheim Pharmaceuticals, Inc. ($16,182) |
All Payment Transactions
534 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $15.04 | General |
| Category: Respiratory | ||||||
| 11/21/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $7.81 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 11/07/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Food and Beverage | In-kind items and services | $33.34 | General |
| Category: Cardiology | ||||||
| 10/31/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $18.41 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/24/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,476.00 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 10/24/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | Cash or cash equivalent | $121.67 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $25.51 | General |
| Category: Respiratory | ||||||
| 10/17/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $20.21 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 10/10/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $26.00 | General |
| Category: ONCOLOGY | ||||||
| 10/07/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $15.71 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 10/03/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $21.67 | General |
| Category: Inflammation | ||||||
| 10/01/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $6.44 | General |
| Category: IMMUNOLOGY | ||||||
| 09/17/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $5.91 | General |
| Category: IMMUNOLOGY | ||||||
| 09/17/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $4.08 | General |
| Category: IMMUNOLOGY | ||||||
| 09/16/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $9.87 | General |
| Category: RESPIRATORY | ||||||
| 09/12/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,321.25 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 09/12/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $85.80 | General |
| Category: NEUROLOGY | ||||||
| 09/05/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $8.64 | General |
| Category: IMMUNOLOGY | ||||||
| 09/05/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $7.20 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 08/29/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $26.50 | General |
| Category: Respiratory | ||||||
| 08/27/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $13.44 | General |
| Category: IMMUNOLOGY | ||||||
| 08/15/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $26.72 | General |
| Category: RESPIRATORY | ||||||
| 08/08/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $23.01 | General |
| Category: Respiratory | ||||||
| 08/01/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $29.76 | General |
| Category: RESPIRATORY | ||||||
| 07/30/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $15.13 | General |
| Category: Respiratory | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EnsoSleep PPG | EnsoData, Inc. | $2,500 | 1 |
| THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | Eli Lilly and Company | $1,400 | 1 |
| A PHASE III, 52 WEEK, RANDOMIZED, DOUBLE BLIND, 3-ARM PARALLEL GROUP S | GlaxoSmithKline, LLC. | $645.93 | 10 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $530.01 | 1 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | Teva Pharmaceuticals USA, Inc. | $156.51 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 2,379 | 3,182 | $589,360 | $193,490 |
| 2022 | 24 | 2,042 | 3,055 | $538,844 | $184,430 |
| 2021 | 24 | 2,177 | 3,127 | $567,332 | $197,061 |
| 2020 | 25 | 1,674 | 2,599 | $543,080 | $168,946 |
Total Patients
8,272
Total Services
11,963
Medicare Billing
$743,926
Procedure Codes
94
All Medicare Procedures & Services
94 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 691 | 1,088 | $204,163 | $70,595 | 34.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 239 | 403 | $110,353 | $39,668 | 35.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 167 | 167 | $68,781 | $20,479 | 29.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 134 | 134 | $36,641 | $10,646 | 29.1% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Facility | 2023 | 59 | 167 | $28,554 | $9,093 | 31.8% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 189 | 189 | $27,726 | $8,491 | 30.6% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 198 | 201 | $31,603 | $6,317 | 20.0% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Office | 2023 | 137 | 142 | $16,233 | $4,987 | 30.7% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 56 | 56 | $8,400 | $4,170 | 49.6% |
| 99307 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 10 minutes | Facility | 2023 | 53 | 145 | $15,817 | $3,864 | 24.4% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 68 | 69 | $5,175 | $2,941 | 56.8% |
| 99305 | Initial nursing facility care with moderate level of medical decision making, per day, if using time, at least 35 minutes | Facility | 2023 | 22 | 22 | $7,073 | $2,296 | 32.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 12 | 12 | $6,195 | $2,161 | 34.9% |
| 94621 | Test for exercise-induced heart and lung stress | Office | 2023 | 17 | 17 | $7,080 | $2,054 | 29.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 59 | 59 | $2,065 | $1,856 | 89.9% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 54 | 55 | $4,720 | $1,510 | 32.0% |
| 94660 | Therapy procedure using a positive pressure ventilator | Office | 2023 | 25 | 26 | $4,250 | $1,293 | 30.4% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 21 | 22 | $2,055 | $474.87 | 23.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 13 | 43 | $1,841 | $460.03 | 25.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 11 | 11 | $480.70 | $132.24 | 27.5% |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | Office | 2023 | 154 | 154 | $154.00 | $3.54 | 2.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 583 | 1,188 | $222,928 | $77,973 | 35.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 193 | 352 | $96,388 | $35,757 | 37.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 108 | 108 | $44,481 | $13,252 | 29.8% |
| 99308 | Follow-up nursing facility visit per day, typically 15 minutes | Facility | 2022 | 58 | 188 | $32,144 | $9,674 | 30.1% |
About Dr. Curtis Mello, MD
Dr. Curtis Mello, MD is a Pulmonary Disease healthcare provider based in North Dartmouth, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1124080312.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Curtis Mello, MD has received a total of $156,440 in payments from pharmaceutical and medical device companies, with $19,123 received in 2024. These payments were reported across 534 transactions from 31 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($83,064).
As a Medicare-enrolled provider, Mello has provided services to 8,272 Medicare beneficiaries, totaling 11,963 services with total Medicare billing of $743,926. Data is available for 4 years (2020–2023), covering 94 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Pulmonary Disease
- Location North Dartmouth, MA
- Active Since 04/04/2006
- Last Updated 08/24/2020
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1124080312
Products in Payments
- SPIRIVA (Drug) $28,986
- YUPELRI (Drug) $13,274
- STIOLTO RESPIMAT (Drug) $7,181
- FASENRA (Biological) $4,431
- FASENRA (Drug) $3,205
- Saxenda (Drug) $1,628
- SPIRIVA RESPIMAT (Drug) $1,422
- BEVESPI AEROSPHERE (Drug) $1,167
- TEZSPIRE (Biological) $698.99
- NUCALA (Biological) $410.23
- OFEV (Drug) $281.33
- TRELEGY ELLIPTA (Drug) $279.50
- DUPIXENT (Biological) $220.71
- SYMBICORT (Drug) $163.13
- Ajovy (Drug) $156.51
- INSPIRE (Device) $124.55
- Arikayce (Drug) $99.99
- WAKIX (Drug) $94.51
- DS Cpap Auto Core-HT (Device) $87.22
- Yupelri (Drug) $85.11
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.